EUDA Market Analysis

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratioForward 7.81
EPS (TTM)$-1.480.0% YoY
Profit margin-40.7%REAL ESTATE
Market cap$33.8MMicro cap

Valuation

Forward P/E
7.81
PEG ratio
P/B
P/S (TTM)
4.96
EV/EBITDA
-25.90

Profitability & growth

ROE (TTM)
0.0%
Operating margin
-34.8%
Revenue growth YoY
78.9%
Dividend yield
Beta
0.68
Last earnings
Oct 1, 2025 · Estimate $0.00 · Reported $-0.03
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About EUDA Health Holdings Limited

Company profile

EUDA Health Holdings Limited is a forward-looking biopharmaceutical company focused on innovating treatments for rare diseases and addressing unmet medical needs. Leveraging advanced technologies, the firm is developing a robust clinical pipeline with a particular emphasis on supportive care and immune modulation. EUDA's strong commitment to research and development positions it favorably in the healthcare landscape, aiming to enhance patient outcomes and expand access to crucial therapies.

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
60 KAKI BUKIT PLACE, SINGAPORE, SINGAPORE
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$33.8M
Shares outstanding$3.0M
52W high$86.00
52W low$5.26

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer